Drug Profile


Alternative Names: AERUMAB 11; AR 101 (anti-Pa mAb) - Aridis Pharmaceuticals; AR-101 - Aridis Pharmaceuticals; KBPA-101

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator Berna Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia; Pseudomonal infections

Most Recent Events

  • 13 Oct 2015 Aridis Pharmaceuticals receives SBIR grant from the National Institutes of Health
  • 12 Jun 2015 Phase-II development in Pseudomonal infections and Nosocomial pneumonia is ongoing in Europe
  • 26 Nov 2014 Development is ongoing Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top